Startup profile · funding coverage
Nava Therapeutics funding, valuation and investors
Biotech developing next-generation lipid nanoparticle (LNP) delivery systems.
Keep track of Nava Therapeutics
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series A
$89M · 2024
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$89M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series a · United States
Investors in latest funding
Other: Andreessen Horowitz , F-Prime Capital
Overview
Nava Therapeutics develops lipid nanoparticle technology for drug delivery — the delivery vehicle critical for mRNA therapies and gene editing. The company raised an $89M Series A in 2024 with Andreessen Horowitz, GV, F-Prime Capital, and Versant Ventures participating.
Why Nava Therapeutics is interesting
Stealth LNP platform play — a16z joined $89M Series A alongside GV and F-Prime as RNA delivery remains the bottleneck for next-gen genetic medicines.
Product & use cases
Nava builds next-generation LNP formulations designed to improve targeted delivery of RNA therapeutics, gene editing payloads, and other nucleic acid medicines beyond first-generation COVID vaccine LNPs.
- Targeted RNA therapeutic delivery
- Next-gen gene editing payload delivery
- Organ-specific LNP formulations for genetic medicine
Key facts
- Series A (2024): $89M with a16z, GV, F-Prime, Versant — Endpoints News
- LNP platform for next-gen genetic medicine delivery
Funding history (newest first)
Series A
2024 $89MInvestors in our directory
Funds linked from Nava Therapeutics's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: Platform LNP chemistry addressing limitations of first-generation formulations — broader tissue targeting than early mRNA vaccine LNPs.
LNP delivery is the bottleneck for genetic medicine expansion beyond liver targeting. Nava competes with established LNP licensors and pharma internal programs. a16z + GV + F-Prime syndicate signals platform potential.
-
Acuitas Therapeutics direct
LNP technology licensor (Comirnaty).
-
Arcturus Therapeutics direct
LNP and self-amplifying RNA.
-
Moderna incumbent
Vertical integrated mRNA with proprietary LNPs.
-
Beam Therapeutics adjacent
Gene editing company needing delivery partners.
Notable stories
- Nava emerged in the post-COVID LNP boom as companies sought delivery beyond first-generation formulations limited largely to liver targeting.
Industries
Related funding articles
Venture Capital Tracker pieces that cover Nava Therapeutics's financing or category context.
FAQs about Nava Therapeutics
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.